top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor
Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor
Pubbl/distr/stampa Cham, : Springer, 2017
Descrizione fisica VII, 419 p. : ill. ; 24 cm
Disciplina 540(Chimica generale)
547(Chimica organica)
615.1(Farmacologia. Farmaci. Farmacia)
615.19(Chimica farmaceutica. Tecnologia farmaceutica. Chimica medica)
616.9041(Microbiologia medica. Farmacoresistenza)
615.580724(Ricerca sperimentale (Sperimentazioni cliniche di farmaci))
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNICAMPANIA-VAN0123334
Cham, : Springer, 2017
Materiale a stampa
Lo trovi qui: Univ. Vanvitelli
Opac: Controlla la disponibilità qui
Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor
Beta-Lactams : Novel Synthetic Pathways and Applications / Bimal K. Banik editor
Edizione [Cham : Springer, 2017]
Pubbl/distr/stampa VII, 419 p., : ill. ; 24 cm
Descrizione fisica Pubblicazione in formato elettronico
Disciplina 540(Chimica generale)
547(Chimica organica)
615.1(Farmacologia. Farmaci. Farmacia)
615.19(Chimica farmaceutica. Tecnologia farmaceutica)
616.9041(Microbiologia medica. Farmacoresistenza)
615.580724(Ricerca sperimentale (Sperimentazioni cliniche di farmaci))
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNICAMPANIA-SUN0123334
VII, 419 p., : ill. ; 24 cm
Materiale a stampa
Lo trovi qui: Univ. Vanvitelli
Opac: Controlla la disponibilità qui
Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff
Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff
Pubbl/distr/stampa Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008
Descrizione fisica 1 online resource (542 p.)
Disciplina 615.580724
Soggetto topico Drug development
Drug development - Simulation methods
Soggetto genere / forma Electronic books.
ISBN 1-281-94698-2
9786611946982
3-527-62267-5
3-527-62268-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Biosimulation in Drug Development; Contents; Preface; List of Contributors; Part I Introduction; 1 Simulation in Clinical Drug Development; 1.1 Introduction; 1.2 Models for Simulations; 1.3 Simulations in Clinical Drug Development: Practical Examples; 1.3.1 Predicting the Outcome of Phase I Studies of Erythropoietin Receptor Agonists; 1.3.2 Simulations for Antimicrobial Dose Selection; 1.3.3 Optimizing the Design of Phase II Dose Finding Studies; 1.3.4 Predicting the Outcome of Phase III Trials Using Phase II Data; 1.4 Conclusions; 2 Modeling of Complex Biomedical Systems; 2.1 Introduction
2.2 Pulsatile Secretion of Insulin2.3 Subcutaneous Absorption of Insulin; 2.4 Bursting Pancreatic β-Cells; 2.5 Conclusions; 3 Biosimulation of Drug Metabolism; 3.1 Introduction; 3.2 Experimental Approaches; 3.2.1 Animal Test Models; 3.2.2 Microbial Models; 3.3 The Biosimulation Approach; 3.4 Ethical Issues; 3.5 PharmBiosim - a Computer Model of Drug Metabolism in Yeast; 3.5.1 General Concept; 3.5.1.1 Chemical Abstraction; 3.5.1.2 Biological Abstraction; 3.5.2 Initial Steps - Experimental Results; 3.5.2.1 Dehalogenation (Pathways II and III); 3.5.2.2 Retro-Claisen Condensation (Pathway IV)
3.5.2.3 Ester Hydrolysis (Pathway VI)3.5.2.4 Competing Pathways and Stereoselectivity; 3.6 Computational Modeling; 3.6.1 Selection of the Modeling Software; 3.6.2 SBML-compatible Software; 3.6.2.1 Cellware; 3.6.2.2 Copasi; 3.6.2.3 Ecell; 3.6.2.4 JigCell; 3.6.2.5 JSim; 3.6.2.6 Systems Biology Workbench; 3.6.2.7 Virtual Cell; 3.6.2.8 XPPAUT; 3.6.3 CellML-compatible Software; 3.6.4 Kinetic Model; 3.6.4.1 Methods; 3.6.4.2 Model Derivation; 3.6.4.3 Results; 3.6.5 Stoichiometric Model; 3.6.5.1 Methods; 3.6.5.2 Model Derivation; 3.6.5.3 Results
3.7 Application of the Model to Predict Drug Metabolism3.8 Conclusions; Part II Simulating Cells and Tissues; 4 Correlation Between In Vitro, In Situ, and In Vivo Models; 4.1 Introduction; 4.2 Biophysical Models of Intestinal Absorption; 4.2.1 Colon; 4.2.2 Small Intestine; 4.2.3 Stomach; 4.3 Influence of Surfactants on Intestinal Permeability; 4.3.1 Absorption Experiments in Presence of Surfactants; 4.3.1.1 Colon; 4.3.1.2 Intestine; 4.3.1.3 Stomach; 4.4 Modeling and Predicting Fraction Absorbed from Permeability Values; 4.4.1 Mass Balance, Time-independent Models
4.4.2 Prediction of the Fraction of Dose Absorbed from In Vitro and In Situ Data4.4.3 Prediction from In Situ Absorption Rate Constant Determined with Closed Loop Techniques; 4.4.4 Prediction from Permeabilities Through Caco-2 Cell Lines; 4.4.5 Prediction from the PAMPA In Vitro System; 4.5 Characterization of Active Transport Parameters; 4.5.1 In Situ Parameter Estimation; 4.5.2 In Vitro-In Situ Correlation; 5 Core-Box Modeling in the Biosimulation of Drug Action; 5.1 Introduction; 5.2 Core-Box Modeling; 5.2.1 Shortcomings of Gray-Box and Minimal Modeling
5.2.1.1 Full-Scale Mechanistic Gray-Box Modeling
Record Nr. UNINA-9910144228403321
Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff
Biosimulation in drug development / / edited by Martin Bertau, Erik Mosekilde, and Hans V. Westerhoff
Pubbl/distr/stampa Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008
Descrizione fisica 1 online resource (542 p.)
Disciplina 615.580724
Soggetto topico Drug development
Drug development - Simulation methods
ISBN 1-281-94698-2
9786611946982
3-527-62267-5
3-527-62268-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Biosimulation in Drug Development; Contents; Preface; List of Contributors; Part I Introduction; 1 Simulation in Clinical Drug Development; 1.1 Introduction; 1.2 Models for Simulations; 1.3 Simulations in Clinical Drug Development: Practical Examples; 1.3.1 Predicting the Outcome of Phase I Studies of Erythropoietin Receptor Agonists; 1.3.2 Simulations for Antimicrobial Dose Selection; 1.3.3 Optimizing the Design of Phase II Dose Finding Studies; 1.3.4 Predicting the Outcome of Phase III Trials Using Phase II Data; 1.4 Conclusions; 2 Modeling of Complex Biomedical Systems; 2.1 Introduction
2.2 Pulsatile Secretion of Insulin2.3 Subcutaneous Absorption of Insulin; 2.4 Bursting Pancreatic β-Cells; 2.5 Conclusions; 3 Biosimulation of Drug Metabolism; 3.1 Introduction; 3.2 Experimental Approaches; 3.2.1 Animal Test Models; 3.2.2 Microbial Models; 3.3 The Biosimulation Approach; 3.4 Ethical Issues; 3.5 PharmBiosim - a Computer Model of Drug Metabolism in Yeast; 3.5.1 General Concept; 3.5.1.1 Chemical Abstraction; 3.5.1.2 Biological Abstraction; 3.5.2 Initial Steps - Experimental Results; 3.5.2.1 Dehalogenation (Pathways II and III); 3.5.2.2 Retro-Claisen Condensation (Pathway IV)
3.5.2.3 Ester Hydrolysis (Pathway VI)3.5.2.4 Competing Pathways and Stereoselectivity; 3.6 Computational Modeling; 3.6.1 Selection of the Modeling Software; 3.6.2 SBML-compatible Software; 3.6.2.1 Cellware; 3.6.2.2 Copasi; 3.6.2.3 Ecell; 3.6.2.4 JigCell; 3.6.2.5 JSim; 3.6.2.6 Systems Biology Workbench; 3.6.2.7 Virtual Cell; 3.6.2.8 XPPAUT; 3.6.3 CellML-compatible Software; 3.6.4 Kinetic Model; 3.6.4.1 Methods; 3.6.4.2 Model Derivation; 3.6.4.3 Results; 3.6.5 Stoichiometric Model; 3.6.5.1 Methods; 3.6.5.2 Model Derivation; 3.6.5.3 Results
3.7 Application of the Model to Predict Drug Metabolism3.8 Conclusions; Part II Simulating Cells and Tissues; 4 Correlation Between In Vitro, In Situ, and In Vivo Models; 4.1 Introduction; 4.2 Biophysical Models of Intestinal Absorption; 4.2.1 Colon; 4.2.2 Small Intestine; 4.2.3 Stomach; 4.3 Influence of Surfactants on Intestinal Permeability; 4.3.1 Absorption Experiments in Presence of Surfactants; 4.3.1.1 Colon; 4.3.1.2 Intestine; 4.3.1.3 Stomach; 4.4 Modeling and Predicting Fraction Absorbed from Permeability Values; 4.4.1 Mass Balance, Time-independent Models
4.4.2 Prediction of the Fraction of Dose Absorbed from In Vitro and In Situ Data4.4.3 Prediction from In Situ Absorption Rate Constant Determined with Closed Loop Techniques; 4.4.4 Prediction from Permeabilities Through Caco-2 Cell Lines; 4.4.5 Prediction from the PAMPA In Vitro System; 4.5 Characterization of Active Transport Parameters; 4.5.1 In Situ Parameter Estimation; 4.5.2 In Vitro-In Situ Correlation; 5 Core-Box Modeling in the Biosimulation of Drug Action; 5.1 Introduction; 5.2 Core-Box Modeling; 5.2.1 Shortcomings of Gray-Box and Minimal Modeling
5.2.1.1 Full-Scale Mechanistic Gray-Box Modeling
Record Nr. UNINA-9910830717703321
Weinheim, Germany : , : WILEY-VCH Verlag GmbH & Co. KGaA, , 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Clinical pharmacology : advances and applications
Clinical pharmacology : advances and applications
Pubbl/distr/stampa [Auckland, NZ], : Dove Medical Press
Descrizione fisica 1 online resource
Disciplina 615.580724
Soggetto topico Clinical pharmacology
Pharmacology, Clinical
Pharmacology
Soggetto genere / forma Periodicals.
Soggetto non controllato Pharmacy, Therapeutics, & Pharmacology
ISSN 1179-1438
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNISA-996200824303316
[Auckland, NZ], : Dove Medical Press
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Clinical pharmacology : advances and applications
Clinical pharmacology : advances and applications
Pubbl/distr/stampa [Auckland, NZ], : Dove Medical Press
Descrizione fisica 1 online resource
Disciplina 615.580724
Soggetto topico Clinical pharmacology
Pharmacology, Clinical
Pharmacology
Soggetto genere / forma Periodicals.
Soggetto non controllato Pharmacy, Therapeutics, & Pharmacology
ISSN 1179-1438
Formato Materiale a stampa
Livello bibliografico Periodico
Lingua di pubblicazione eng
Record Nr. UNINA-9910139253303321
[Auckland, NZ], : Dove Medical Press
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
Pubbl/distr/stampa Hoboken, NJ, : Wiley, c2009
Descrizione fisica 1 online resource (1247 p.)
Disciplina 615.1
615.580724
615/.1
Altri autori (Persone) GadShayne C. <1948->
Collana Pharmaceutical Development Series
Soggetto topico Drugs - Testing
Clinical trials
Soggetto genere / forma Electronic books.
ISBN 1-282-36844-3
9786612368448
0-470-46636-7
0-470-46635-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology
10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards
16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index
Record Nr. UNINA-9910455072803321
Hoboken, NJ, : Wiley, c2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
Pubbl/distr/stampa Hoboken, NJ, : Wiley, c2009
Descrizione fisica 1 online resource (1247 p.)
Disciplina 615.1
615.580724
615/.1
Altri autori (Persone) GadShayne C. <1948->
Collana Pharmaceutical Development Series
Soggetto topico Drugs - Testing
Clinical trials
ISBN 1-282-36844-3
9786612368448
0-470-46636-7
0-470-46635-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology
10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards
16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index
Record Nr. UNINA-9910778685003321
Hoboken, NJ, : Wiley, c2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
Clinical trials handbook [[electronic resource] /] / edited by Shayne Cox Gad
Pubbl/distr/stampa Hoboken, NJ, : Wiley, c2009
Descrizione fisica 1 online resource (1247 p.)
Disciplina 615.1
615.580724
615/.1
Altri autori (Persone) GadShayne C. <1948->
Collana Pharmaceutical Development Series
Soggetto topico Drugs - Testing
Clinical trials
ISBN 1-282-36844-3
9786612368448
0-470-46636-7
0-470-46635-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials
9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology
10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards
16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; Index
Record Nr. UNINA-9910816984703321
Hoboken, NJ, : Wiley, c2009
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The Cox Model and Its Applications [[electronic resource] /] / by Mikhail Nikulin, Hong-Dar Isaac Wu
The Cox Model and Its Applications [[electronic resource] /] / by Mikhail Nikulin, Hong-Dar Isaac Wu
Autore Nikulin Mikhail
Edizione [1st ed. 2016.]
Pubbl/distr/stampa Berlin, Heidelberg : , : Springer Berlin Heidelberg : , : Imprint : Springer, , 2016
Descrizione fisica 1 online resource (131 p.)
Disciplina 615.580724
Collana SpringerBriefs in Statistics
Soggetto topico Statistics 
Biostatistics
Epidemiology
Statistical Theory and Methods
Statistics for Life Sciences, Medicine, Health Sciences
ISBN 3-662-49332-2
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Introduction: Several Classical Data Examples for Survival Analysis -- Elements of Survival Analysis -- The Cox Proportional Hazards Model -- The AFT, GPH, LT, Frailty, and GLPH Models -- Cross-effect Models of Survival Functions -- The Simple Cross-effect Model -- Goodness-of-Fit for the Cox Model -- Remarks on Computations in Parametric and Semiparametric Estimation -- Cox Model for Degradation and Failure Time Data -- References -- Index.
Record Nr. UNINA-9910254075403321
Nikulin Mikhail  
Berlin, Heidelberg : , : Springer Berlin Heidelberg : , : Imprint : Springer, , 2016
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui